They found that miR-34 was able to overcome HGF-induced gefitinib resistance in HCC827 and PC-9 cells by modulating c-Met and downstream pathway molecules, suggesting a new strategy for reversing HGF-induced resistance to gefitinib in lung cancers [24]. The gene discussed is MET; the disease is lung cancer.